Canopy Growth Corporation v. Gw Pharma Limited

CourtCourt of Appeals for the Federal Circuit
DecidedApril 24, 2023
Docket22-1603
StatusUnpublished

This text of Canopy Growth Corporation v. Gw Pharma Limited (Canopy Growth Corporation v. Gw Pharma Limited) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Canopy Growth Corporation v. Gw Pharma Limited, (Fed. Cir. 2023).

Opinion

Case: 22-1603 Document: 49 Page: 1 Filed: 04/24/2023

NOTE: This disposition is nonprecedential.

United States Court of Appeals for the Federal Circuit ______________________

CANOPY GROWTH CORPORATION, Plaintiff-Appellant

v.

GW PHARMA LIMITED, GW RESEARCH LIMITED, Defendants-Appellees ______________________

2022-1603 ______________________

Appeal from the United States District Court for the Western District of Texas in No. 6:20-cv-01180-ADA, Judge Alan D. Albright. ______________________

Decided: April 24, 2023 ______________________

DAVID G. WILLE, Baker Botts LLP, Dallas, TX, argued for plaintiff-appellant. Also represented by MELISSA MUENKS, KURT M. PANKRATZ, CLARKE STAVINOHA; MICHAEL HAWES, Houston, TX.

GERALD J. FLATTMANN, JR., Cahill Gordon & Reindel LLP, New York, NY, argued for defendants-appellees. Also represented by JESSE SNYDER, AMY R. UPSHAW, King & Spalding LLP, Washington, DC. ______________________ Case: 22-1603 Document: 49 Page: 2 Filed: 04/24/2023

Before LOURIE, TARANTO, and STARK, Circuit Judges. TARANTO, Circuit Judge. Canopy Growth Corp. sued GW Pharma Ltd. and GW Research Ltd. (collectively, GW) in the United States Dis- trict Court for the Western District of Texas, alleging in- fringement of at least claims 1–25 of its U.S. Patent No. 10,870,632. The district court issued an order construing the sole disputed claim limitation: “CO2 in liquefied form under subcritical pressure and temperature conditions.” Canopy Growth Corp. v. GW Pharmaceuticals PLC, No. 20- cv-01180, 2021 WL 8015834, at *4–15 (W.D. Tex. Nov. 27, 2021). Based on the district court’s construction, the par- ties stipulated to non-infringement, and the court then en- tered final judgment in favor of GW on infringement and dismissed GW’s remaining affirmative defenses and coun- terclaims without prejudice. Canopy appeals. Because the phrase “subcritical pressure and temperature conditions,” as used in the claims here, requires both pressure and tem- perature to be subcritical, we affirm. I The ’632 patent describes and claims processes for pro- ducing an extract containing tetrahydrocannabinol (THC) and/or cannabidiol (CBD) from cannabis using liquid car- bon dioxide (i.e., CO2). CO2 can exist in the solid, liquid, and gas phases. But when temperature and pressure are high enough, CO2 can transition from the liquid or gas phase into a supercritical fluid state. The lowest combina- tion of temperature and pressure at which this transition can occur is the critical point; only if both temperature and pressure are above the critical point will CO2 enter the su- percritical fluid state. CO2 can be described as subcritical when either its tem- perature or its pressure is below the critical point, and, put- ting aside its solid phase (which is not relevant here), CO2 Case: 22-1603 Document: 49 Page: 3 Filed: 04/24/2023

CANOPY GROWTH CORPORATION v. GW PHARMA LIMITED 3

can be in the subcritical state as either a liquid or a gas, depending on the specific temperature and pressure of the CO2. When its temperature is supercritical but its pres- sure is subcritical, CO2 will form a gas because the pres- sure is not sufficient to force the CO2—expanding due to the high temperature—to liquify. In contrast, when its temperature is subcritical but its pressure is supercritical, the CO2 will form a liquid. And when both temperature and pressure are subcritical, CO2 can form either a liquid or a gas, depending on the specific temperature and pres- sure. The critical-point temperature for CO2 is 31°C, and the critical-point pressure for CO2 is 73.8 bar (or 72.8 atm). The parties do not dispute any of those principles, which are depicted in the CO2 phase diagram below. 1

1 Canopy contends in its reply brief that “[t]he pres- ence of impurities in the CO2 can result in liquefied CO2 at a temperature above what is generally understood as the critical temperature of CO2.” Reply Br. at 3 n.1 (citing J.A. 1215). Neither the document Canopy cites nor the argu- ment Canopy makes appears in Canopy’s briefing before Case: 22-1603 Document: 49 Page: 4 Filed: 04/24/2023

J.A. 90. Independent claim 1 of the ’632 patent recites 1. A process for producing an extract contain- ing Tetrahydrocannabinol (THC) and/or canna- bidiol (CBD), and optionally the carboxylic acids thereof, from a cannabis plant material or a pri- mary extract thereof, said process comprising: (1) subjecting the cannabis plant material or primary extract thereof to CO2 in liquefied form under subcritical pressure and tem- perature conditions to extract cannabinoid components; and (2) reducing the pressure and/or tempera- ture to separate tetrahydrocannabinol and/or cannabidiol, and optionally the carboxylic ac- ids thereof, from the CO2. ’632 patent, col. 14, lines 30–41 (bolding added for empha- sis). The only other independent claim, claim 14, is rele- vantly similar, and all claims of the ’632 patent include the limitation at issue. The ’632 patent’s specification lists the phrase at issue among itemized temperature and pressure conditions for

the district court, notwithstanding GW’s argument before the district court that CO2 is a gas under these conditions. Even if this court could take judicial notice of the document for its content, which has not been requested or justified, Canopy has doubly forfeited this argument. See In re Google Technology Holdings LLC, 980 F.3d 858, 863 (Fed. Cir. 2020) (arguments not presented to the reviewed tribu- nal are generally forfeited); Aventis Pharma S.A. v. Hos- pira, Inc., 675 F.3d 1324, 1332–33 (Fed. Cir. 2012) (arguments not raised before us until reply briefing are for- feited). Case: 22-1603 Document: 49 Page: 5 Filed: 04/24/2023

CANOPY GROWTH CORPORATION v. GW PHARMA LIMITED 5

CO2 that are “[i]n accordance with the invention.” Id., col. 5, lines 6–20. Specifically, it provides that extraction can occur with the aid of CO2 under supercritical pressure and temperature conditions at a temperature in the range of approx[.] 31° C. to 80° C. and at a pres- sure in the range of approx. 75 bar to 500 bar, or in the subcri[t]i[c]al range at a temperature of ap- prox. 20° C. to 30° C. and a supercritical pressure of approx. 100 bar to 350 bar; or extracted under subcri[t]i[c]al pressure and temperature condi- tions; and the obtained primary extract is sepa- rated under subcri[t]i[c]al conditions, or under conditions that are subcri[t]i[c]al in terms of pres- sure and supercritical in terms of temperature. Id. The limitation at issue, with the other possible CO2 conditions quoted above, also appears in the prosecution history. The ’632 patent issued from a continuation of Ap- plication No. 10/399,362. During prosecution of that appli- cation, the applicant sought claims to these conditions in a claimed process that it described as reciting three “alterna- tive steps,” J.A. 372 (emphasis omitted), depicted below:

J.A. 366. As described by the applicant during prosecution, these alternative steps permitted extraction via CO2 under Case: 22-1603 Document: 49 Page: 6 Filed: 04/24/2023

“(a) supercritical pressure and temperature conditions; or (b) subcritical temperature range and a supercritical pres- sure; or (c) subcritical pressure and temperature condi- tions.” J.A. 372–73. The ’362 application issued with claims directed to these steps as U.S. Patent No. 8,895,078. For the application that gave rise to the ’632 patent, Application No. 14/276,165, the prosecution history starts off similarly, in that the applicant began by seeking claims directed to the same three alternative steps. J.A. 399. But in response to an examiner rejection of the claims over prior art that discloses the use of supercritical fluid CO2 for extraction, Webster (U.S. Patent No.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Oatey Co. v. IPS CORP.
514 F.3d 1271 (Federal Circuit, 2008)
Aventis Pharma S.A. v. Hospira, Inc.
675 F.3d 1324 (Federal Circuit, 2012)
World Class Technology Corp v. Ormco Corporation
769 F.3d 1120 (Federal Circuit, 2014)
Personalized Media v. Apple Inc.
952 F.3d 1336 (Federal Circuit, 2020)
Simo Holdings Inc. v. Hong Kong Ucloudlink Network
983 F.3d 1367 (Federal Circuit, 2021)
University of Massachusetts v. L"oreal S.A.
36 F.4th 1374 (Federal Circuit, 2022)

Cite This Page — Counsel Stack

Bluebook (online)
Canopy Growth Corporation v. Gw Pharma Limited, Counsel Stack Legal Research, https://law.counselstack.com/opinion/canopy-growth-corporation-v-gw-pharma-limited-cafc-2023.